Fibrinogen Abnormalities, Dysfibrinogenemia, and Fibrinolytic Disorders

Fibrinogen is the soluble plasma protein that thrombin converts into the fibrin meshwork of a clot, and disorders of its quantity or quality, together with disorders of the fibrinolytic system that dissolves fibrin, sit at the final common step of hemostasis. This topic describes congenital and acquired fibrinogen abnormalities — afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia — and disorders of fibrinolysis, along with their laboratory recognition.

Definition

Fibrinogen disorders are congenital or acquired abnormalities in the amount (afibrinogenemia, hypofibrinogenemia) or function (dysfibrinogenemia) of fibrinogen; fibrinolytic disorders are imbalances in the plasmin-mediated system that breaks down fibrin, either of which can disturb the bleeding-thrombosis balance.

Scope

Coverage includes the classification of congenital fibrinogen disorders into quantitative (absent or reduced) and qualitative (dysfunctional) types, the mixed type, and the laboratory tests (functional fibrinogen activity versus antigen) that separate them, plus a brief orientation to disorders of excessive or deficient fibrinolysis. It is a reference and laboratory-pattern overview and gives no treatment guidance.

Core questions

• How is fibrinogen converted to fibrin at the final step of coagulation?
• How are congenital fibrinogen disorders classified into quantitative and qualitative types?
• How does a discrepancy between fibrinogen activity and antigen reveal a dysfunctional molecule?
• How can fibrinolytic imbalance tip toward either bleeding or thrombosis?

Key concepts

• Fibrinogen-to-fibrin conversion by thrombin
• Afibrinogenemia and hypofibrinogenemia (quantitative defects)
• Dysfibrinogenemia (qualitative defect)
• Activity-to-antigen ratio in diagnosis
• Plasmin and the fibrinolytic system
• Hyperfibrinolysis versus hypofibrinolysis
• ISTH classification of congenital fibrinogen disorders

Mechanisms

Fibrinogen circulates as a soluble precursor; at the end of the coagulation cascade thrombin cleaves it to fibrin monomers that polymerize and are cross-linked by factor XIII into a stable clot. Quantitative defects — complete absence (afibrinogenemia) or reduced levels (hypofibrinogenemia) — limit clot formation, while qualitative defects (dysfibrinogenemia) produce a normal amount of an abnormal molecule that clots poorly or, in some variants, abnormally promotes thrombosis. Laboratory diagnosis rests on comparing functional fibrinogen activity with immunologic fibrinogen antigen: concordant low values indicate a quantitative defect, whereas a low activity-to-antigen ratio indicates a dysfunctional protein. The fibrinolytic system, in which plasmin degrades fibrin, can itself be deranged: excessive fibrinolysis favors bleeding, while deficient fibrinolysis favors thrombosis.

Clinical relevance

These disorders explain a subset of bleeding and, less commonly, thrombotic presentations and are identified through specific coagulation testing. The entry describes the biology and laboratory classification as reference material and does not offer diagnostic thresholds or treatment recommendations, which fall to specialist evaluation.

Epidemiology

Congenital fibrinogen disorders are rare; afibrinogenemia is inherited in an autosomal recessive manner and is uncommon, while dysfibrinogenemia is often inherited dominantly and may be discovered incidentally on coagulation testing. Acquired fibrinogen abnormalities are far more frequent and accompany conditions such as liver disease and consumptive coagulopathy.

History

Fibrinogen was among the earliest recognized clotting components, and its conversion to fibrin was central to early models of coagulation. As factor assays matured, the distinction between quantitative and qualitative fibrinogen defects became clear, and the International Society on Thrombosis and Haemostasis later issued a consensus classification of congenital fibrinogen disorders to standardize diagnosis.

Key figures

• Alessandro Casini
• Philippe de Moerloose
• Robert Macfarlane

Seminal works

• macfarlane-1964
• casini-2018

Frequently asked questions

What distinguishes dysfibrinogenemia from hypofibrinogenemia?

Hypofibrinogenemia is a quantitative defect with reduced amounts of normal fibrinogen, whereas dysfibrinogenemia is a qualitative defect with a normal amount of a dysfunctional fibrinogen. The two are separated in the laboratory by comparing functional activity with antigen levels.

Can a fibrinogen disorder cause clotting rather than bleeding?

Yes. Although most fibrinogen disorders predispose to bleeding, some dysfibrinogenemia variants are associated instead with a thrombotic tendency, reflecting the protein's central role in the bleeding-thrombosis balance.